Grantham, Mayo, Van Otterloo & Co (GMO)’s ResMed RMD Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.25M	Buy	+18,923	New	+$4.72M	0.01%	345
2016 Q1	–	Sell	-37,303	Closed	-$2M	–	620
2015 Q4	$2M	Sell	37,303 -35,200	-49%	-$1.98M	0.01%	336
2015 Q3	$3.69M	Sell	72,503 -37,400	-34%	-$2.01M	0.01%	271
2015 Q2	$6.2M	Sell	109,903 -800	-0.7%	-$50.5K	0.02%	232
2015 Q1	$7.95M	Sell	110,703 -200	-0.2%	-$13K	0.02%	214
2014 Q4	$6.22M	Sell	110,903 -23,811	-18%	-$1.24M	0.02%	237
2014 Q3	$6.64M	Sell	134,714 -40,600	-23%	-$2.07M	0.02%	243
2014 Q2	$8.88M	Buy	175,314 +4,500	+3%	+$223K	0.02%	210
2014 Q1	$7.63M	Buy	170,814 +84,343	+98%	+$3.79M	0.02%	232
2013 Q4	$4.07M	Sell	86,471 -329	-0.4%	-$16.7K	0.01%	341
2013 Q3	$4.58M	Buy	86,800 +24,458	+39%	+$1.19M	0.01%	322
2013 Q2	$2.81M	Buy	+62,342	New	+$2.96M	0.01%	367

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s RMD Position: Q1 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) opened a new position in ResMed (RMD) in Q1 2026: 18,923 shares worth $4.25M. The stake represents 0.01% of the portfolio and ranks #345 among its holdings. This is a return to the name: Grantham, Mayo, Van Otterloo & Co (GMO) previously reported a position in RMD as recently as Q4 2015.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in RMD in Q2 2013 and has held it in 12 quarters since. The position peaked at $8.88M in Q2 2014. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Grantham, Mayo, Van Otterloo & Co (GMO) held 18,923 shares of ResMed worth $4.25M as of Q1 2026.
ResMed was a new Grantham, Mayo, Van Otterloo & Co (GMO) position in Q1 2026.
ResMed made up 0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q1 2026, its #345 holding.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ResMed in Q2 2013 and has held it in 12 quarters since.
Grantham, Mayo, Van Otterloo & Co (GMO)'s ResMed position peaked at $8.88M in Q2 2014.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.